Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Angharad de Cates and Dr Liliana Capitão were just two of the department's researchers presenting and publishing new research at the European College of Neuropsychopharmacology (ECNP) Conference 2021, in Lisbon.

Banner image of the 34th ECNP conference 2-5 October 2021, saying 'Welcome to the future of CNS treatments'

Depressed adolescents' brains shown to mute distressing information

Scientists have measured brain activity in young people with and without depression, and found that the brains of depressed adolescents give a muted reaction to distressing images. Previous research with depressed adults does not show this effect, implying that brain development in adolescence may have specific vulnerabilities to unsettling information, and that perhaps the depressed adolescent brain avoids information which in the end could aggravate the depression. Antidepressant treatment was shown to restore this depressed brain activity to ‘healthy’ levels.  This work was presented at the ECNP conference.

The researchers, from the University of Oxford, compared brain activity of 29 depressed adolescents with that of 16 healthy adolescents, aged 13 to 18. They found that when depressed adolescents were shown a series of photos of distressing images, there was reduced activity, as shown on an fMRI brain scan, (compared to non-depressed adolescents) in brain areas related to visual processing; the occipital pole (which processes visual information, found at the rear of the brain) and the fusiform gyrus (which is involved in the processing of faces, body and colours, found near the brain stem). The images depicted scenarios such as someone crying, someone visibly hurt, someone being attacked.

Lead researcher, Dr Liliana Capitão, University of Oxford, said:


'The ability to regulate emotions is key to social and emotional development in adolescents. What we have seen in this study makes us believe that depressed adolescents may avoid distressing information, which could potentially intensify their experience of depression.  There are also other possible interpretations for this intriguing pattern, so further research is needed to confirm our ideas. For instance, this could also reflect a form of “emotional numbness”, where depressed adolescents shut down their emotions and do not feel “involved” in what’s happening around them, or even reflect difficulties with taking another person’s perspective, as the images showed distressing situations that were happening to others. This effect has not been found in previous work using the same distressing images in adults with depression, which could imply that there are potential vulnerabilities in the brains of depressed adolescents which are not found in the brains of depressed adults.'

Read more about this research, which is currently under review in Psychological Medicine.

Intestinal drug shown to boost memory and cognition

The development of drugs to treat cognitive problems in patients with mental illness may be a step closer after a team of researchers discovered that an existing drug – used to treat constipation – may be able to boost our ability to think more clearly.

Severe psychiatric disorders can have a devastating impact on a patient’s life.  Cognitive impairments - ranging from decreased attention and working memory to disrupted social cognition and language - are widespread in psychiatric disorders such as major depression, schizophrenia, and bipolar disorder. These common problems are poorly treated with current medications and often have a large impact on people’s lives, and so scientists are searching for ways of improving or restoring these functions.

Previous animal studies have shown that the drugs which target one of the serotonin receptors (the 5-HT4 receptor) have shown promise in improving cognitive function (serotonin is the neurotransmitter which is targeted by SSRI antidepressants). However, it has been difficult to translate these animal findings into humans because of worries about side effects. Now a group of UK researchers have tested an existing approved drug, prucalopride, which targets the 5-HT4 receptor, and found that it may improve cognition. Prucalopride is primarily prescribed for constipation, and has an acceptable level of side effects if taken under medical supervision.

Presenting the work at the ECNP conference (with simultaneous publication), lead researcher, Dr Angharad de Cates of the University of Oxford said:


'Participants who had taken prucalopride for 6 days performed much better than those receiving placebo on the memory test; the prucalopride group identified 81% of previously viewed images versus 76% in the placebo group. Statistical tests indicate that this was a fairly large effect – such an obvious cognitive improvement with the drug was a surprise to us.'

Read more about this research, Déjà-vu? Neural and behavioural effects of the 5-HT4 receptor agonist, prucalopride, in a hippocampal-dependent memory task, published in Translational Psychiatry.

Coverage of this research story: The Telegraph Neuroscience News SciShow (from 2.33 mins).

For more information about the ECNP Conference 2021.


Please follow the link below to read the news on the NIHR BRC website.

Similar stories

New Study Shows Simvastatin Can Change the Way People Experience Certain Emotions

This new study examines the effects of simvastatin on emotional processing, reward learning, verbal memory, and inflammation.

Oxford researchers part of major UK initiative to understand chronic pain

Oxford pain researchers are playing a major role in a new multi-million pound research programme launched by a consortium of funders, including UKRI, Versus Arthritis, Eli Lilly and the Medical Research Foundation.

Anxiety Disorders Among Children, Assessment and Working with Families

Anxiety disorders are the most common mental health disorders among children, yet there is limited guidance on the process of assessing child anxiety disorders and sharing diagnostic outcomes with families.

Landmark New Clinical Trial Shows Benefits of Automated Virtual Reality (VR) Treatment for Severe Psychological Problems

The gameChange automated VR program is designed to treat agoraphobia in patients with psychosis. In the largest ever clinical trial of virtual reality for mental health, gameChange especially helped people whose anxiety had previously left them virtually housebound.

UK-Japanese Collaboration Researches Mental Health Challenges Faced by Young People and their Families

Dr Simona Skripkauskaite, Departments of Psychiatry and Experimental Psychology, University of Oxford, is the UK lead for one of the ten collaborative research projects jointly awarded by the Economic and Social Research Council (ESRC), the Arts and Humanities Research Council (AHRC) and the Japan Society for the Promotion of Science (JSPS), to address the challenges presented by the global pandemic.

Department of Psychiatry Recognition Awards

Today we announce the prize winners of the first Department of Psychiatry Recognition Awards. One award is designed to offer early career researchers (ECRs) the opportunity to showcase their work, motivations and aspirations for research into mental health. Alongside this we launch the 'Good Citizen' award, where all department members have been able to make nominations.